IP Library Granted Patent US 9,000,041
Granted Patent B2
US 9,000,041 · App. 13/925,818 · Granted Apr 7, 2015

Hydroxyl compounds and compositions for cholesterol management and related uses

Inventors: Jean-Louis Henri Dasseux (Toulouse, FR); Carmen Daniela Oniciu (Toulouse, FR)
Assignee: Esperion Therapeutics, Inc.
C07C59/245C07C31/20C07C31/22C07C31/24C07C59/11C07C59/285C07C59/29C07C59/46C07C59/48C07C59/54C07C62/02C07C62/06C07C65/17C07C69/757C07D213/80C07D309/10C07D309/12C07D405/12C07F9/093C07F9/094C07F9/117C07F9/2425C07F9/4423C07C2101/02C07C2101/04C07C2101/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,000,041
App. No.
13/925,818
Granted
Apr 7, 2015
Kind
B2
Abstract

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Claims (45)

1. A method for treating dyslipidemia, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula I to treat the dyslipidemia:

or a pharmaceutically acceptable salt thereof, wherein:

(a) each occurrence of m is independently an integer ranging from 0 to 5;

(b) each occurrence of n is independently an integer ranging from 3 to 7;

(c) X is (CH 2 ) z , wherein z is an integer from 0 to 4;

(d) each occurrence of R 1 , R 2 , R 11 , and R 12 is independently H, (C 1 -C 6 )alkyl, or phenyl, wherein R 1 , R 2 , R 11 , and R 12 are not each simultaneously H; and

(e) each occurrence of Y 1 and Y 2 is independently OH, COOH, COOR 3 ,

wherein:

R 3 is (C 1 -C 6 )alkyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, or (C 1 -C 6 )alkoxy.

2. The method of claim 1 , wherein each occurrence of Y 1 and Y 2 is independently OH, COOR 3 , or COOH.

3. The method of claim 1 , wherein m is 0.

4. The method of claim 1 , wherein m is 1.

5. The method of claim 1 , wherein n is 4.

6. The method of claim 1 , wherein n is 5.

7. The method of claim 1 , wherein z is 0.

8. The method of claim 1 , wherein the compound is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

9. A method for treating dyslipidemia, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula

or a pharmaceutically acceptable salt thereof, to treat the dyslipidemia.

10. The method of claim 9 , wherein the compound is

11. The method of claim 1 , wherein R 1 , R 2 , R 11 , and R 12 are (C 1 -C 6 )alkyl.

12. The method of claim 11 , wherein Y 1 and Y 2 are COOH.

13. The method of claim 12 , wherein X is (CH 2 ) z , and z is 0.

14. The method of claim 13 , wherein m is 0.

15. The method of claim 1 , wherein the dyslipidemia is hypercholesterolemia.

16. The method of claim 8 , wherein the dyslipidemia is hypercholesterolemia.

17. The method of claim 9 , wherein the dyslipidemia is hypercholesterolemia.

18. The method of claim 10 , wherein the dyslipidemia is hypercholesterolemia.

19. The method of claim 12 , wherein the dyslipidemia is hypercholesterolemia.

20. The method of claim 14 , wherein the dyslipidemia is hypercholesterolemia.

21. A method for treating a cardiovascular disease selected from the group consisting of atherosclerosis, stroke, ischemia, peripheral vascular disease, coronary heart disease, myocardial infarction, cerebral infarction, and restenosis, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula I to treat the cardiovascular disease:

or a pharmaceutically acceptable salt thereof, wherein:

each occurrence of m is independently an integer ranging from 0 to 5;

each occurrence of n is independently an integer ranging from 3 to 7;

X is (CH 2 ) z , wherein z is an integer from 0 to 4;

each occurrence of R 1 , R 2 , R 11 , and R 12 is independently H or (C 1 -C 6 )alkyl, wherein R 1 , R 2 , R 11 , and R 12 are not each simultaneously H;

each occurrence of Y 1 and Y 2 is independently OH, COON, or COOR 3 ; and

R 3 is (C 1 -C 6 )alkyl.

22. The method of claim 21 , wherein R 1 , R 2 , R 11 , and R 12 are (C 1 -C 6 )alkyl.

23. The method of claim 22 , wherein Y 1 and Y 2 are COOH.

24. The method of claim 23 , wherein z is 0.

25. The method of claim 24 , wherein m is 0.

26. The method of claim 21 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

27. The method of claim 21 , wherein the compound is

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2024
From: EIGER III SA LLC
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 067963/0094 →
SECURITY INTEREST Recorded Jun 28, 2019
From: ESPERION THERAPEUTICS, INC.
To: EIGER III SA LLC, AS PURCHASER AGENT
Reel/Frame 049623/0629 →
MERGER Recorded Oct 14, 2014
From: ESPERION THERAPEUTICS, INC.
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 033946/0330 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2013
From: DASSEUX, JEAN-LOUIS HENRI; ONICIU, CARMEN DANIELA
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 030727/0824 →
Continuity (6)
Continuation 13470825 · May 14, 2012
Continuation 12870184 · Aug 27, 2010
Division 11680105 · Feb 28, 2007
Division 10743470 · Dec 23, 2003
Provisional Application 60441795 · Jan 23, 2003
Related Publication 20130289117A1 · Oct 31, 2013